glp 1 drugs covered by medicare GLP-1 Drug Coverage CMS Issues Coverage Guidance on

The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs (n=83,464) or SGLT-2 inhibitors (n=78,366), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs (n=108,322) or DPP-4 inhibitors (n=55,411)

Secondary outcomes were each of these events considered separately

Engineering new ligands that specifically target multiple G protein-coupled receptors with desired activity profiles requires time-consuming and expensive cycles of design-make-test-analyse work

Treatment results vary from person to person

A cell uses various mechanisms for regulating optimal glucose levels